Onconova Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.962; its P/E ratio is -1.05; Onconova Therapeutics is scheduled to report earnings on May 14, 2024, and the estimated EPS forecast is $-0.23. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 57.00K	$ 57.00K	$ 56.00K	$ 56.00K	$ 57.00K
Gross Profit	$ 57.00K	$ 57.00K	$ 56.00K	$ 56.00K	-
EBIT	$ -4.74M	$ -4.25M	$ -5.78M	$ -6.07M	$ -5.64M
EBITDA	$ -4.73M	$ -4.25M	$ -5.77M	$ -6.07M	$ -5.64M
Net Income Common Stockholders	$ -4.74M	$ -4.25M	$ -5.78M	$ -5.42M	$ -5.40M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 0.00	$ 29.73M	$ 34.22M	$ 38.76M	$ 42.61M
Total Assets	$ 27.04M	$ 30.47M	$ 35.06M	$ 39.37M	$ 43.78M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ 0.00	$ -29.73M	$ -34.22M	$ -38.76M	$ -42.61M
Total Liabilities	$ 12.52M	$ 11.57M	$ 12.19M	$ 11.06M	$ 10.41M
Stockholders Equity	$ 14.52M	$ 18.90M	$ 22.88M	$ 28.31M	$ 33.37M
Cash Flow	-
Free Cash Flow	$ -4.48M	$ -4.49M	$ -4.54M	$ -3.88M	$ -3.90M
Operating Cash Flow	$ -4.47M	$ -4.49M	$ -4.54M	$ -3.88M	$ -3.90M
Investing Cash Flow	$ -14.00K	-	-	-	-
Financing Cash Flow	-	-	-	-	$ 0.00

Currency in USD

Onconova Therapeutics Earnings and Revenue History

Income Statement >

Onconova Therapeutics Debt to Assets

Balance Sheet >

Onconova Therapeutics Cash Flow

Cash Flow >

Onconova Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing